When evaluating coagulation, what does an abnormal PT or aPTT typically prompt clinicians to investigate?

• A. Only urinary disorders
• B. Exclusively heart disease
• C. Liver enzyme variations
• D. Potential coagulopathy etiologies such as vitamin K deficiency, liver disease, or anticoagulant exposure

Answer: (D)

Prothrombin time (PT) and activated partial thromboplastin time (aPTT) are screening tests for the coagulation cascade. When either test is abnormal, it signals a possible coagulopathy—an issue with clotting factor activity or with factors that regulate coagulation. The reason clinicians investigate vitamin K status, liver function, or anticoagulant exposure is that these are common and reversible causes of abnormal PT or aPTT. Vitamin K deficiency reduces the synthesis of several clotting factors, liver disease impairs the liver’s ability to produce those factors, and anticoagulants (like warfarin or heparin) directly affect the activity of clotting factors, prolonging these times. The PT mainly reflects the extrinsic and common pathways, while the aPTT reflects the intrinsic and common pathways, so abnormalities can point to problems in those pathways and prompt a workup for these etiologies. Urinary disorders or heart disease don’t directly explain prolonged PT or aPTT, and liver enzyme variations aren’t the primary focus of these coagulation screening tests, even though liver disease can be a cause.